Individualized therapy for growth hormone deficiency.

Area of Science:

• Pediatrics
• Endocrinology
• Pharmacology

Background:

• Human growth hormone (hGH) therapy has over 40 years of clinical use for children with short stature.
• Growth hormone deficiency (GHD) is the primary indication for hGH treatment in pediatric populations.
• Diagnosis of GHD relies on auxologic features and biochemical testing.

Purpose of the Study:

• To evaluate the efficacy and safety of growth hormone treatment in children.
• To explore the use of insulin-like growth factor-I (IGF-I) response for optimizing hGH dosing.
• To provide guidance on adjusting hGH dosage based on IGF-I levels.

Main Methods:

• Clinical experience accrued over 40 years.
• Diagnosis based on auxologic features and biochemical testing.
• Dosing algorithms utilizing insulin-like growth factor-I (IGF-I) response.

Main Results:

• hGH therapy demonstrates a satisfactory safety and efficacy record.
• IGF-I response algorithms appear to reflect true patient needs and optimize treatment.
• Dose adjustments (increases or reductions) based on IGF-I levels are suggested for improved outcomes.

Conclusions:

• Growth hormone therapy is a well-established treatment for pediatric short stature due to GHD.
• IGF-I response monitoring provides a valuable tool for optimizing hGH dosage.
• Individualized dose adjustments based on IGF-I levels are crucial for maximizing treatment efficacy and safety.